

SUPPORTING INFORMATION

Title: Organocatalytic Asymmetric β -Hydroxylation of α,β -Unsaturated Ketones

Author(s): Armando Carlone, Giuseppe Bartoli, Marcella Bosco, Fabio Pesciaioli, Paolo Ricci, Letizia Sambri, Paolo Melchiorre*

Ref. No.: O200700873

General Methods. The ^1H and ^{13}C NMR spectra were recorded at 600 MHz and 150 MHz or 400 MHz and 100 MHz, respectively. The chemical shifts (δ) are referenced to residual signals of the solvents (CHCl_3 – 7.26 ppm for ^1H NMR and 77.0 ppm for ^{13}C NMR). Coupling constants are given in Hz. Carbon types were determined by DEPT ^{13}C NMR experiments. The following abbreviations are used to indicate the multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad signal. Purification of reaction products was carried out by flash chromatography (FC) on silica gel (230–400 mesh) according to the method of Still.¹ Organic solutions were concentrated under reduced pressure on a Büchi rotary evaporator. Mass spectra were obtained from the Department of Organic Chemistry “A. Mangini” Mass Spectroscopy facility. Optical rotations are reported as follows: $[\alpha]_D^{25}$ (c in g per 100 mL, solvent). All reactions were carried out in air and using undistilled solvent, without any precautions to exclude moisture unless otherwise noted.

Materials. Commercial grade reagents and solvents were used without further purification; otherwise, where necessary, they were purified as recommended.² Oximes **1** were purchased from AlfaAesar and used as received. α,β -Unsaturated ketones were purchased and used as received, prepared by Wittig reaction with commercially available acetylmethylene-triphenylphosphorane ($\text{R}_2 = \text{Me}$), or with Grignard reaction on the corresponding unsaturated aldehyde followed by oxidation with MnO_2 ($\text{R}_2 = \text{Et}$). *N*-protected amino acids were purchased from Aldrich or Fluka and used as received. 9-Amino(9-deoxy)*epi*-hydroquinine was prepared from commercially available hydroquinine following the literature procedure.³

Determination of Enantiomeric Purity. Chiral HPLC analysis was performed on an Agilent 1100-series instrumentation. Daicel Chiralpak AD-H or AS-H columns and Daicel Chiralcel OD-H with *i*-PrOH/hexane as the eluent were used. HPLC traces were compared to racemic samples prepared by benzylamine·TFA-catalyzed reaction.

Determination of Absolute Configuration. The absolute configuration of the optically active compound **3e** was determined by reductive cleavage to afford **4** and subsequent comparison of the measured optical rotation of **4** with literature value.⁴ All other absolute configurations were assigned by analogy based on a uniform reaction mechanism and the uniform elution order observed in the HPLC chromatograms.

¹ W. C. Still, M. Kahn, A. J. Mitra, *J. Org. Chem.* 1978, **43**, 2923.


² W. L. F. Armarengo, D. D. Perrin, In *Purification of Laboratory Chemicals*, 4th ed.; Butterworth Heinemann: Oxford, 1996.

³ B. Vakulya, Sz. Varga, A. Csámpai, T. Soos, *Org. Lett.* 2005, **7**, 1967.

⁴ E. M. Carreira, W. Lee and R. A. Singer, *J. Am. Chem. Soc.*, 1995, **117**, 3649.


Experimental Procedures

General Procedure for the Organocatalytic β -hydroxylation of α,β -unsaturated ketones. All the reactions were carried out in undistilled Et₂O without any precautions to exclude water. In an ordinary test tube equipped with a magnetic stirring bar, 9-amino(9-deoxy)epi-hydroquinine (10 or 20 mol%) and D-N-Boc phenylglycine (15 or 30 mol%) as the chiral counter-anion were dissolved in 1 mL of Et₂O. The solution was stirred for 20 minutes at room temperature to allow the formation of the catalytic salt **A**. After addition of α,β -unsaturated ketones (0.2 mmol), the mixture was stirred at room temperature for 10 minutes. Then oxime (0.6 mmol, 3 equiv.) was added in one portion, the tube was closed with a rubber stopper and stirring was continued for the indicated time. Then the crude reaction mixture was diluted with hexane (2 mL) and flushed through a plug of silica, using hexane/Et₂O 1/1 as the eluent. Solvent was removed *in vacuo*, and the residue was purified by flash chromatography to yield the desired product.



2,4-Dimethoxy-benzaldehyde O-[1-(2-oxo-propyl)-hexyl]-oxime **3a** (Table 2, entry 1). The reaction was carried out at RT for 40 h following the general procedure. The title compound was isolated by column chromatography (hexane/Acetone = 95/5) in 52% yield and


90% ee. The ee was determined by HPLC analysis using a Chiralcel OD-H column (80/20 hexane/*i*-PrOH; flow rate 0.75 mL/min; $\lambda = 214, 254$ nm; $\tau_{minor} = 6.2$ min; $\tau_{major} = 6.5$ min). $[\alpha]_D^{25} = +2.8$ ($c = 1.2$, CHCl₃, 90% ee). HRMS: m/z calcd for C₁₈H₂₇NO₄: 321.1940; found: 321.1943. ¹H NMR (400 MHz, CDCl₃): $\delta = 0.88$ (t, $J = 6.8$ Hz, 3H), 1.21-1.50 (m, 6H), 1.52-1.75 (m, 2H), 2.20 (s, 3H), 2.86 (dd, $J = 4.8, 15.6$ Hz, 1H), 2.56 (dd, $J = 7.4, 15.6$ Hz, 1H), 3.80 (s, 3H), 3.81 (s, 3H), 4.55-4.61 (m, 1H), 6.41 (d, $J = 2.4$ Hz, 1H), 6.48 (dd, $J = 2.4, 8.8$ Hz, 1H), 7.67 (d, $J = 8.8$ Hz, 1H), 8.34 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 13.4, 22.5, 25.0, 30.9, 31.7, 34.0, 48.6, 55.4, 55.5, 79.4, 98.1, 105.4, 113.9, 127.2, 144.2, 158.7, 162.3, 207.7$.



2,4-Dimethoxy-benzaldehyde O-[1-(2-oxo-butyl)-hexyl]-oxime **3b** (Table 2, entry 2). The reaction was carried out at RT for 48 h following the general procedure. The title compound was isolated by column chromatography (hexane/Acetone = 95/5) in 56% yield and


94% ee. The ee was determined by HPLC analysis using a Chiralcel OD-H column (90/10 hexane/*i*-PrOH; flow rate 0.75 mL/min; $\lambda = 214, 254$ nm; $\tau_{minor} = 6.6$ min; $\tau_{major} = 7.1$ min). $[\alpha]_D^{25} = -8.1$ ($c = 1.5$, CHCl₃, 94% ee). HRMS: m/z calcd for C₁₉H₂₉NO₄: 335.2097; found: 335.2095. ¹H NMR (400 MHz, CDCl₃): $\delta = 0.88$ (t, $J = 6.8$ Hz, 3H), 1.04 (t, $J = 7.2$ Hz, 3H), 1.25-1.47 (m, 6H), 1.52-1.75 (m, 2H), 3.74 (q, $J = 7.2$ Hz, 2H), 2.54 (dd, $J = 5.2, 15.2$ Hz, 1H), 2.56 (dd, $J = 7.2, 15.2$ Hz, 1H), 3.80 (s,

3H), 3.82 (s, 3H), 4.55-4.61 (m, 1H), 6.41 (d, $J=2.4$ Hz, 1H), 6.48 (dd, $J=2.4, 8.8$ Hz, 1H), 7.67 (d, $J=8.8$ Hz, 1H), 8.34 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 7.6, 14.0, 22.5, 25.1, 31.7, 34.0, 36.8, 47.3, 55.4, 55.5, 79.4, 98.1, 105.4, 114.0, 127.2, 144.1, 158.7, 162.3, 210.2$.




2,4-Dimethoxy-benzaldehyde O-(1-methyl-3-oxo-butyl)-oxime – 3c (Table 2, entry 3). The reaction was carried out at RT for 40 h following the general procedure. The title compound was isolated by column chromatography (hexane/Acetone = 95/5) in 53% yield and

80% ee. The ee was determined by HPLC analysis using a Chiralcel OD-H column (90/10 hexane/*i*-PrOH; flow rate 0.75 mL/min; $\lambda = 214, 254$ nm; $\tau_{\text{minor}} = 9.9$ min; $\tau_{\text{major}} = 10.4$ min). $[\alpha]_{\text{D}}^{\text{rt}} = +4.9$ ($c = 0.8, \text{CHCl}_3, 80\%$ ee). HRMS: m/z calcd for $\text{C}_{14}\text{H}_{19}\text{NO}_4$: 265.131409; found: 265.13140. ^1H NMR (400 MHz, CDCl_3): $\delta = 1.32$ (d, $J=6.4$ Hz, 3H), 2.20 (s, 3H), 2.56 (dd, $J=5.6, 15.6$ Hz, 1H), 2.90 (dd, $J=7.2, 15.6$ Hz, 1H), 3.80 (s, 3H), 3.82 (s, 3H), 4.68-4.75 (m, 1H), 6.42 (d, $J=2.4$ Hz, 1H), 6.48 (dd, $J=2.4, 8.8$ Hz, 1H), 7.67 (d, $J=8.8$ Hz, 1H), 8.34 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 19.9, 30.8, 50.0, 55.4, 55.5, 75.4, 98.2, 105.4, 113.9, 127.3, 144.5, 158.8, 162.3, 207.3$.



2,4-Dimethoxy-benzaldehyde O-(1-methyl-3-oxo-pentyl)-oxime – 3d (Table 2, entry 4). The reaction was carried out at RT for 60 h following the general procedure. The title compound was isolated by column chromatography (hexane/Acetone = 95/5) in 46% yield and


88% ee. The ee was determined by HPLC analysis using a Chiralcel OD-H column (95/5 hexane/*i*-PrOH; flow rate 0.75 mL/min; $\lambda = 214, 254$ nm; $\tau_{\text{minor}} = 11.7$ min; $\tau_{\text{major}} = 12.4$ min). $[\alpha]_{\text{D}}^{\text{rt}} = -4.8$ ($c = 1.2, \text{CHCl}_3, 88\%$ ee). HRMS: m/z calcd for $\text{C}_{15}\text{H}_{21}\text{NO}_4$: 279.147059; found: 279.14720. ^1H NMR (400 MHz, CDCl_3): $\delta = 1.05$ (t, $J=7.2$ Hz, 3H), 1.32 (d, $J=6.4$ Hz, 3H), 2.49 (q, $J=7.2$ Hz, 2H), 2.52 (dd, $J=5.6, 15.6$ Hz, 1H), 2.90 (dd, $J=6.8, 15.6$ Hz, 1H), 3.80 (s, 3H), 3.82 (s, 3H), 4.68-4.75 (m, 1H), 6.42 (d, $J=2.4$ Hz, 1H), 6.48 (dd, $J=2.4, 8.8$ Hz, 1H), 7.67 (d, $J=8.8$ Hz, 1H), 8.33 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 7.6, 19.9, 36.8, 48.8, 55.4, 55.5, 75.5, 98.2, 105.4, 113.9, 127.3, 144.4, 158.8, 162.3, 209.8$.



2,4-Dimethoxy-benzaldehyde O-(3-oxo-1-phenethyl-butyl)-oxime – 3e (Table 2, entry 5). The reaction was carried out at RT for 40 h following the general procedure. The title compound was isolated by column chromatography (hexane/Acetone = 95/5) in 55% yield and


90% ee. The ee was determined by HPLC analysis using a Chiralpak AS-H column (90/10 hexane/*i*-PrOH; flow rate 0.75 mL/min; $\lambda = 214, 254$ nm; $\tau_{\text{minor}} = 18.6$ min; $\tau_{\text{major}} = 20.4$ min). $[\alpha]_{\text{D}}^{\text{rt}} = +10.4$ ($c =$

1.0, CHCl₃, 90% ee). HRMS: *m/z* calcd for C₂₁H₂₅NO₄: 355,1784; found: 355,1780. ¹H NMR (600 MHz, CDCl₃): δ = 1.87-1.93 (m, 1H), 1.99-2.06 (m, 1H), 2.17 (s, 3H), 2.58 (dd, *J* = 5.4, 15.6 Hz, 1H), 2.68-2.73 (m, 1H), 2.78-2.83 (m, 1H), 2.91 (dd, *J* = 7.2, 15.6 Hz, 1H), 3.80 (s, 3H), 3.81 (s, 3H), 4.60-4.64 (m, 1H), 6.42 (d, *J* = 2.4 Hz, 1H), 6.48 (dd, *J* = 2.4, 9.0 Hz, 1H), 7.15-7.27 (m, 5H), 7.28-2.83 (m, 1H), 7.68 (d, *J* = 9.0 Hz, 1H), 8.38 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 30.8, 31.7, 35.8, 48.5, 55.4, 55.5, 78.5, 98.1, 105.4, 113.8, 125.8, 127.3, 128.3, 128.4, 141.9, 144.5, 158.8, 162.4, 207.4.




2,4-Dimethoxy-benzaldehyde O-(3-oxo-1-propyl-pentyl)-oxime – 3f (Table 2, entry 6). The reaction was carried out at RT for 55 h following the general procedure. The title compound was isolated by column chromatography (hexane/Acetone = 95/5) in 55% yield and

92% ee. The ee was determined by HPLC analysis using a Chiralcel OD-H column (90/10 hexane/*i*-PrOH; flow rate 0.75 mL/min; λ = 214, 254 nm; τ_{minor} = 6.9 min; τ_{major} = 7.4 min). [α]_D²⁵ = -12.6 (*c* = 1.1, CHCl₃, 92% ee). HRMS: *m/z* calcd for C₁₇H₂₅NO₄: 307.178359; found: 307.1783. ¹H NMR (400 MHz, CDCl₃): δ = 0.91-0.96 (m, 3H), 1.00-1.06 (m, 3H), 1.38-1.80 (m, 4H), 2.43-2.62 (m, 3H), 2.84-2.93 (m, 1H), 3.80 (s, 3H), 3.82 (s, 3H), 4.57-4.62 (m, 1H), 6.42 (d, *J* = 2.4 Hz, 1H), 6.48 (dd, *J* = 2.4, 8.4 Hz, 1H), 7.68 (d, *J* = 8.4 Hz, 1H), 8.33 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 7.6, 14.0, 18.7, 36.1, 36.9, 47.4, 55.4, 55.6, 79.2, 98.1, 105.4, 113.9, 127.2, 144.1, 158.7, 162.3, 210.2.




2,4-Dimethoxy-benzaldehyde O-(3-oxo-1-triisopropylsilyloxypropyl-pentyl)-oxime – 3g (Table 2, entry 7).


The reaction was carried out at RT for 60 h following the general procedure. The title compound was isolated by column chromatography (hexane/Acetone = 95/5) in 35% yield and 80% ee. The ee was determined by HPLC analysis using a Chiralpak AS-H column (95/5 hexane/*i*-PrOH; flow rate 0.75 mL/min; λ = 214, 254 nm; τ_{major} = 5.4 min; τ_{minor} = 6.7 min). [α]_D²⁵ = -19.2 (*c* = 0.5, CHCl₃, 80% ee). ¹H NMR (600 MHz, CDCl₃): δ = 0.89-1.07 (m, 24H), 2.43-2.47 (m, 2H), 2.74-2.76 (m, 2H), 3.69-3.89 (m, 2H), 3.73 (s, 3H), 3.75 (s, 3H), 4.57-4.62 (m, 1H), 6.34 (d, *J* = 2.4 Hz, 1H), 6.41 (dd, *J* = 2.4, 9.0 Hz, 1H), 7.60 (d, *J* = 9.0 Hz, 1H), 8.26 (s, 1H); ¹³C NMR (150 MHz, CDCl₃): δ = 7.6, 11.9, 18.0, 36.7, 43.6, 55.4, 55.5, 64.2, 79.8, 98.2, 105.4, 113.9, 127.3, 144.6, 158.8, 162.3, 209.9.



4 (**(R)-4-Hydroxy-6-phenylhexan-2-one**⁴ – **4** (Scheme 4). To a suspension of oxime ether **3e** (0.15 M) in AcOH/H₂O (1:1 v/v) was added Zn powder (40 equiv) under argon atmosphere. After being stirred for 24h the reaction mixture was diluted with Et₂O, filtered and extracted with Et₂O. The organic phase was dried over MgSO₄ and concentrated under reduced pressure.⁵ The title compound was isolated by column chromatography (hexane/AcOEt = 80/20) in 96% yield and 88% ee. The ee was determined by HPLC analysis using a Chiralpak AD-H column (90/10 hexane/*i*-PrOH; flow rate 0.75 mL/min; $\lambda = 214, 254$ nm; $\tau_{minor} = 10.3$ min; $\tau_{major} = 11.4$ min). $[\alpha]_D^{25} = -12.0$ ($c = 1.1$, CHCl₃, 88% ee). ¹H NMR (400 MHz, CDCl₃): $\delta = 1.63-1.73$ (m, 1H), 1.78-1.87 (m, 1H), 2.16 (s, 3H), 2.58-2.61 (m, 2H), 2.65-2.86 (m, 2H), 3.10 (bs, 1H), 4.02-4.08 (m, 1H), 7.15-7.27 (m, 5H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 30.7, 31.7, 37.9, 49.9, 66.7, 125.8, 128.3, 128.4, 147.8, 209.8$.



syn-5 (**(2S,4R)-6-Phenylhexane-2,4-diol** – **syn-5** (Scheme 1). The syn reduction was carried out following the literature procedure⁶ yielding crude *syn* compound **5** in a 9/1 diastereomeric ratio. The title compound was isolated by column chromatography (CH₂Cl₂/Acetone = 90/10) in 99% yield, 9/1 dr and 88% ee. The ee was determined by HPLC analysis using a Chiralpak AD-H column (90/10 hexane/*i*-PrOH; flow rate 0.75 mL/min; $\lambda = 214, 254$ nm; $\tau_{major} = 9.4$ min; $\tau_{minor} = 9.8$ min). $[\alpha]_D^{25} = +11.7$ ($c = 0.6$, CHCl₃, 88% ee). ¹H NMR (600 MHz, CDCl₃): $\delta = 1.19$ (d, $J = 6.6$ Hz, 3H), 1.50-1.59 (m, 2H), 1.71-1.80 (m, 2H), 2.63-2.77 (m, 2H), 3.29 (bs, 1H), 3.43 (bs, 1H), 3.86-3.90 (m, 1H), 4.00-4.05 (m, 1H), 7.17-7.29 (m, 5H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 24.2, 31.6, 39.7, 44.6, 69.1, 72.2, 125.8, 128.3, 128.4, 141.9$.



anti-5 (**(2R,4R)-6-Phenylhexane-2,4-diol** – **anti-5** (Scheme 1). To a solution of **4** (0.1 M) in AcOH was added Me₄NBH₄ (2 equiv) under argon atmosphere. After being stirred for 4h the reaction mixture was diluted with Et₂O, quenched with H₂O, and extracted with Et₂O.⁷ The organic phase was dried over MgSO₄ and concentrated under reduced pressure yielding crude *anti* compound **5** in a 2.5/1 diastereomeric ratio. The title compound was isolated by column chromatography (gradient CH₂Cl₂/Acetone from 99/1 to 9/1) in 38% yield, 95/5 dr and 88% ee. The ee was determined by HPLC analysis using a Chiralpak AD-H column (90/10 hexane/*i*-PrOH; flow rate 0.75 mL/min; $\lambda = 214, 254$ nm; $\tau_{minor} = 10.0$ min; $\tau_{major} = 10.6$ min). $[\alpha]_D^{25} = +2.7$ ($c = 0.6$, CHCl₃, 88% ee). ¹H NMR (400 MHz, CDCl₃): $\delta = 1.23$ (d, $J = 9.6$ Hz, 3H), 1.62-1.89 (m, 4H), 2.65-2.84 (m, 2H), 3.95-4.00 (m, 1H), 4.14-4.20 (m, 1H), 7.17-7.29 (m, 5H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 23.6, 32.2, 39.0, 44.0, 65.5, 68.8, 125.8, 128.3, 128.4, 141.9$.

⁵ H. Miyabe, A. Matsumura, K. Moriyama, and Y. Takemoto, *Org. Lett.*, 2004, **6**, 4631.

⁶ G. Bartoli, M. Bosco, M. C. Bellucci, R. Dalpozzo, E. Marcantoni and L. Sambri, *Org. Lett.*, 2000, **2**, 45.

⁷ We have used a modified version of the literature procedure: D. A. Evans, K. T. Chapman and E. M. Carreira, *J. Am. Chem. Soc.*, 1988, **110**, 3560.

Representative NMR spectra

